223 related articles for article (PubMed ID: 23287700)
41. A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats.
Järbe TU; LeMay BJ; Thakur GA; Makriyannis A
Pharmacol Biochem Behav; 2016 Sep; 148():46-52. PubMed ID: 27264437
[TBL] [Abstract][Full Text] [Related]
42. Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
Järbe TU; Gifford RS; Makriyannis A
Eur J Pharmacol; 2010 Dec; 648(1-3):133-8. PubMed ID: 20854804
[TBL] [Abstract][Full Text] [Related]
43. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
44. The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex.
Limebeer CL; Rock EM; Mechoulam R; Parker LA
Br J Pharmacol; 2012 Nov; 167(5):1126-36. PubMed ID: 22671779
[TBL] [Abstract][Full Text] [Related]
45. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.
Vann RE; Warner JA; Bushell K; Huffman JW; Martin BR; Wiley JL
Eur J Pharmacol; 2009 Aug; 615(1-3):102-7. PubMed ID: 19470387
[TBL] [Abstract][Full Text] [Related]
46. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.
Storr MA; Bashashati M; Hirota C; Vemuri VK; Keenan CM; Duncan M; Lutz B; Mackie K; Makriyannis A; Macnaughton WK; Sharkey KA
Neurogastroenterol Motil; 2010 Jul; 22(7):787-96, e223. PubMed ID: 20180825
[TBL] [Abstract][Full Text] [Related]
47. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.
Wiley JL; Breivogel CS; Mahadevan A; Pertwee RG; Cascio MG; Bolognini D; Huffman JW; Walentiny DM; Vann RE; Razdan RK; Martin BR
Eur J Pharmacol; 2011 Jan; 651(1-3):96-105. PubMed ID: 21114999
[TBL] [Abstract][Full Text] [Related]
48. A pharmacological paradox: may a neutral antagonist shift an agonist concentration-response curve to the left?
Feuerstein TJ
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):601-3. PubMed ID: 24866501
[TBL] [Abstract][Full Text] [Related]
49. Apparent CB
Grim TW; Morales AJ; Thomas BF; Wiley JL; Endres GW; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2017 Jul; 362(1):210-218. PubMed ID: 28442584
[TBL] [Abstract][Full Text] [Related]
50. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.
Pertwee RG
Curr Med Chem; 2010; 17(14):1360-81. PubMed ID: 20166927
[TBL] [Abstract][Full Text] [Related]
51. Age-related changes in CB1 receptor expression and function and the behavioral effects of cannabinoid receptor ligands.
Ginsburg BC; Hensler JG
Pharmacol Biochem Behav; 2022 Feb; 213():173339. PubMed ID: 35077729
[TBL] [Abstract][Full Text] [Related]
52. Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability.
O'Brien LD; Wills KL; Segsworth B; Dashney B; Rock EM; Limebeer CL; Parker LA
Pharmacol Biochem Behav; 2013 Jan; 103(3):597-602. PubMed ID: 23103902
[TBL] [Abstract][Full Text] [Related]
53. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.
Jergas B; Schulte K; Bindila L; Lutz B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):621-8. PubMed ID: 24853577
[TBL] [Abstract][Full Text] [Related]
54. Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.
Silva GB; Atchison DK; Juncos LI; García NH
Am J Physiol Renal Physiol; 2013 Feb; 304(4):F376-81. PubMed ID: 23220721
[TBL] [Abstract][Full Text] [Related]
55. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
56. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
Seillier A; Martinez AA; Giuffrida A
Neuropsychopharmacology; 2013 Aug; 38(9):1816-24. PubMed ID: 23563893
[TBL] [Abstract][Full Text] [Related]
57. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.
Sink KS; McLaughlin PJ; Wood JA; Brown C; Fan P; Vemuri VK; Peng Y; Olszewska T; Thakur GA; Makriyannis A; Parker LA; Salamone JD
Neuropsychopharmacology; 2008 Mar; 33(4):946-55. PubMed ID: 17581535
[TBL] [Abstract][Full Text] [Related]
58. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Kinsey SG; Mahadevan A; Zhao B; Sun H; Naidu PS; Razdan RK; Selley DE; Imad Damaj M; Lichtman AH
Neuropharmacology; 2011; 60(2-3):244-51. PubMed ID: 20849866
[TBL] [Abstract][Full Text] [Related]
59. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
60. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
